On 17 October 2025, Boston Scientific Corporation (NYSE: BSX) announced that it will acquire the remaining equity of Nalu Medical, Inc., a privately-held medical-technology company specialising in minimally invasive neurostimulation solutions for chronic peripheral-nerve pain.
This deal, valued at approximately US$533 million in cash, marks a strategic move that we’ll refer to as the “Nalu Acquisition”.
Strategic context and rationale
Nalu Medical’s flagship offering, the Nalu Neurostimulation System, features a miniaturised, battery-free implantable pulse generator wirelessly powered via an external disc and controlled through a smartphone app. The system is designed for adults suffering from chronic pain of peripheral-nerve origin (for example shoulder, lower back and knee).
Nalu’s system received FDA 510(k) clearance in 2019. In clinical trials (COMFORT and COMFORT 2), results showed 87% of participants achieved more than 50% pain reduction at 12 months, and 79% achieved an average 64% pain relief at six months.
Boston Scientific has been a strategic investor in Nalu since 2017, making this move a full-acquisition to integrate and scale the technology.
Under terms of the agreement, Boston expects Nalu to generate in excess of US$60 million in revenue in 2025, with year-over-year growth in excess of 25% in 2026. The transaction is expected to be immaterial to adjusted EPS in 2026, slightly accretive in 2027 and increasingly accretive thereafter.
Key implications of the Nalu Acquisition
-
Portfolio expansion in pain-management devices – With this acquisition, Boston Scientific adds a differentiated peripheral nerve stimulation (PNS) platform to its existing neuromodulation offerings (which include spinal cord stimulation, basivertebral nerve ablation, radio-frequency ablation). This enables access to a broader chronic-pain patient segment via less invasive therapy.
-
Commercial scaling opportunity – Nalu is presented as rising quickly (with >25% projected growth in 2026). For Boston Scientific, this represents a growth engine in a market of chronic pain where unmet needs remain high and demand for novel alternatives is increasing.
-
Integration and execution risk – While Boston forecasts accretion starting 2027, as with many device acquisitions, successful integration (especially reimbursement, regulatory, supply chain, physician adoption) will be critical. Analysts note margin pressure and competitive dynamics as key watch-points.
-
Signal to market and consolidation trend – The Nalu Acquisition signals that major med-tech players regard PNS as a key segment and are willing to allocate significant capital to secure position. It may prompt further consolidation or partnerships in this therapeutic area.
Why this matters for the medical-device sector
Chronic pain remains a significant global health-care challenge. Device-based neurostimulation therapies are increasingly accepted, supported by data, and reimbursed in more markets. The Nalu Acquisition by Boston Scientific underscores the trend that neuromodulation is not just for spinal cord stimulation anymore — peripheral nerve stimulation is becoming mainstream. For hospitals, clinicians and payers, this means more therapeutic options, potentially lower invasive-therapy burdens and shifting dynamics in device portfolios.
From an investor and stakeholder perspective, the deal suggests Boston Scientific is targeting high-growth niche segments within its broad device ecosystem. The commitment to the Nalu platform shows belief in growth beyond core cardiovascular or rhythm-management domains.
Looking ahead, the key milestones will include:
-
Completion of the transaction in H1 2026 (subject to closing conditions).
-
Integration of Nalu’s commercial operations into Boston’s global footprint, rollout of PNS beyond initial indications.
-
Realising synergies, scaling R&D and reimbursement efforts, and achieving the accretion in EPS as projected in 2027 and beyond.
Outlook
If Boston Scientific executes well on integration, the Nalu Acquisition could become a meaningful contributor to its neuromodulation business and diversify revenue streams in the pain-device segment. It may also pressure competitors like Abbott Laboratories, Medtronic plc and others to accelerate PNS-related strategies. The deal will be watched closely in 2026 for signs of commercial traction, reimbursement uptake and margin improvements.
In summary, the Nalu Acquisition is a bold strategic move by Boston Scientific into a high-potential segment of chronic pain therapy, aligning with broader med-tech trends and underscoring the company’s long-term growth ambition.
